These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3521864)

  • 1. [The importance of nonspecific immunotherapy in Hodgkin's disease. Experience of the first comprehensive control team in the Department of General Medicine at Charles University in Prague].
    Dienstbier Z; Foltýnová V; Citavý M
    Cas Lek Cesk; 1986 Apr; 125(17):518-23. PubMed ID: 3521864
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary evaluation of immunotherapy in patients with Hodgkin's disease.
    Zywicka-Lopaciuk H; Konopka L; Karpowicz M; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Małkowska-Zwierz W; Pawelski S
    Arch Immunol Ther Exp (Warsz); 1981; 29(6):739-55. PubMed ID: 7349093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BCG immunotherapy in malignant lymphogranuloma].
    Dientsbier Z; Foltýnová V; Hermanská Z; Chytrý P; Maríková E
    Sb Lek; 1991 May; 93(3-4):84-94. PubMed ID: 1853142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Our experience with nonspecific immunotherapy of tumour processes by BCG vaccine (author's transl)].
    Andrysek O; Mostecký H; Dienstbier Z
    Cas Lek Cesk; 1974 Sep; 113(38):1170-2. PubMed ID: 4607393
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation of prognostic factors in Hodgkin's disease. Experience of the comprehensive rationale team in treating patients with Hodgkin's disease].
    Foltýnová V
    Cas Lek Cesk; 1986 May; 125(22):684-90. PubMed ID: 3708676
    [No Abstract]   [Full Text] [Related]  

  • 6. BCG vaccination in Hodgkin's lymphogranuloma.
    Kolár V; Opat P; Hrdlicková N
    Neoplasma; 1979; 26(1):13-6. PubMed ID: 431752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of Hodgkin's disease at the Cancer Institute, Madras.
    Shanta V; Sastri DV; Sagar TG; Sasikala K; Krishnamurthi S
    Clin Oncol; 1982 Mar; 8(1):5-15. PubMed ID: 7075045
    [No Abstract]   [Full Text] [Related]  

  • 8. [BCG-non specific immunotherapy of Hodgkin's disease. Preliminary results from a controlled investigation].
    Hoerni B; Chauvergne J; Hoerni-Simon G; Durand M; Lagarde C
    Acta Haematol; 1974; 52(4):214-9. PubMed ID: 4217526
    [No Abstract]   [Full Text] [Related]  

  • 9. MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study.
    Vinciguerra V; Coleman M; Pajak TF; Rafla S; Stutzman L; Gomez G; Weil M; Brunner K; Cuttner J; Nissen N; Leventhal B; Gottlieb A
    Cancer Clin Trials; 1981; 4(2):99-105. PubMed ID: 7018726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [B.C.G. osteitis after immunotherapy (author's transl)].
    Metz R; Stines J; Parache R; Weber B
    Nouv Presse Med; 1978 May; 7(21):1835-8. PubMed ID: 673735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protocol of the Comprehensive Care Team for the treatment of Hodgkin's disease].
    Dienstbier Z; Zámecník J; Hermanská Z; Beska F
    Sb Lek; 1988; 90(2-3):67-75. PubMed ID: 3368746
    [No Abstract]   [Full Text] [Related]  

  • 12. Bacille Calmette-Guérin as maintenance therapy for non-Hodgkin's lymphoma.
    Thomas JW; Plenderleith IH; Landi S; Basco VE; Clements DV
    Can Med Assoc J; 1983 Sep; 129(5):439-42. PubMed ID: 6349765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical use of BCG vaccine in stimulating host resistance to cancer.
    Villasor RP
    J Philipp Med Assoc; 1965 Sep; 41(9):619-32. PubMed ID: 5321970
    [No Abstract]   [Full Text] [Related]  

  • 14. [Studies of monocytopoiesis in patients with malignant disease and after immunostimulation with BCG, using 3H-thymidine as a DNA-label (author's transl)].
    Schmitt E; Meuret G; Waldermann F; Hoffmann G
    Nuklearmedizin; 1982 Apr; 21(2):49-54. PubMed ID: 7099973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic results in lymphogranulomatosis and their relationship to immunological reactivity].
    Dienstbier Z; Foltýnová V; Hlavatý V; Kopricová H; Masopust J
    Vopr Onkol; 1981; 27(4):22-6. PubMed ID: 7233870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hodgkin's disease: eleven years' experience at West Virginia University.
    Blum D; Harley JB; Krall JM
    W V Med J; 1972 Jul; 68(7):184-6. PubMed ID: 4504181
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hodgkin's disease--diagnostic basis and therapy in light of randomized clinical trials].
    Jurczak W; Nowak WS; Mensah P; Skotnicki AB
    Przegl Lek; 1999; 56 Suppl 1():90-100. PubMed ID: 10494189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
    Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
    Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hodgkin's disease: ten years' experience of a combined lymphoma clinic. The Prince of Wales Hospital Oncology Cooperative Group (lymphoma), Sidney.
    Med J Aust; 1980 Feb; 1(3):118-21. PubMed ID: 7374519
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.